Maravai LifeSciences Holdings, Inc. $MRVI Shares Purchased by Eversept Partners LP

Eversept Partners LP boosted its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 147.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 718,582 shares of the company’s stock after buying an additional 427,909 shares during the quarter. Eversept Partners LP owned 0.28% of Maravai LifeSciences worth $2,335,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its position in Maravai LifeSciences by 80.5% in the fourth quarter. AQR Capital Management LLC now owns 111,131 shares of the company’s stock worth $361,000 after buying an additional 49,551 shares during the last quarter. Jain Global LLC acquired a new position in Maravai LifeSciences in the 4th quarter worth approximately $36,000. Russell Investments Group Ltd. boosted its stake in Maravai LifeSciences by 18.2% in the 4th quarter. Russell Investments Group Ltd. now owns 132,741 shares of the company’s stock worth $431,000 after purchasing an additional 20,434 shares during the period. State of Wisconsin Investment Board acquired a new position in Maravai LifeSciences in the 4th quarter worth approximately $133,000. Finally, Yost Capital Management LP acquired a new position in Maravai LifeSciences in the 4th quarter worth approximately $410,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Weiss Ratings raised shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Wells Fargo & Company raised their price objective on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $5.50.

Maravai LifeSciences Trading Up 4.2%

Shares of NASDAQ:MRVI opened at $5.22 on Thursday. The firm has a fifty day moving average of $4.18 and a two-hundred day moving average of $3.67. The firm has a market capitalization of $1.35 billion, a P/E ratio of -7.35 and a beta of 0.72. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.99 and a 12-month high of $5.32. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. The company had revenue of $65.84 million during the quarter, compared to analyst estimates of $53.00 million. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. On average, equities analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total transaction of $126,500.00. Following the transaction, the general counsel owned 360,767 shares in the company, valued at approximately $1,825,481.02. This trade represents a 6.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.